Enveric Biosciences, Inc.
ENVB evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $6.4M
- Lead Asset:
- eb-003 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for ENVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENVB
Enveric Biosciences, Inc. is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for psychiatric disorders, with its lead candidate EB-003 in preclinical development.
Key risk: Preclinical stage risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$6.4M
Cash Runway
—
Lead Asset
eb-003 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Enveric Biosciences, Inc..
Enveric Biosciences, Inc. is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for psychiatric disorders, with its lead candidate EB-003 in preclinical development.
- Enveric is focused on developing non-hallucinogenic neuroplastogens for depression, anxiety, addiction, and other psychiatric disorders [sec_mda · as of 2026-08-14].
- Lead candidate EB-003 is designed to selectively engage 5-HT2A and 5-HT1B receptors, aiming for fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience [sec_mda · as of 2026-08-14].
- EB-003 has completed short-term toxicology studies and advanced into IND-enabling, GLP-compliant safety pharmacology, ADMET, and longer-term toxicology studies [sec_mda · as of 2026-08-14].
- The company unveiled the EVM401 Series on February 25, 2025, to broaden its pipeline with additional non-hallucinogenic molecules [sec_mda · as of 2026-08-14].
- As of 2026-06-30, Enveric reported a net loss of -$3.0M and shareholders' equity of $8.1M [sec].
What works
- Enveric's lead candidate EB-003 is described as the first known compound to selectively engage both 5-HT2A and 5-HT1B receptors, potentially offering a differentiated mechanism for depression and anxiety without hallucinations [sec_mda · as of 2026-08-14].
- The company leverages the Psybrary™, a proprietary library of over 20 patent families covering a million potential molecular structures, providing a broad discovery platform [sec_mda · as of 2026-08-14].
- Enveric has advanced EB-003 into IND-enabling studies, indicating progress toward clinical development [sec_mda · as of 2026-08-14].
What to weigh
- Enveric is a preclinical-stage company with no approved products, and its lead candidate EB-003 has not yet entered human trials, carrying significant development risk [sec_mda · as of 2026-08-14].
- The company reported a net loss of -$3.0M for the quarter ended June 30, 2026, and has an accumulated deficit, reflecting ongoing cash burn without revenue [sec].
- Enveric faces substantial uncertainty regarding regulatory approval, clinical trial design, and commercialization, as noted in its forward-looking statements [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
EB-003 is designed to selectively engage 5-HT2A and 5-HT1B receptors for antidepressant and anxiolytic effects.
“our belief that EB-003 is the first known compound to selectively engage both 5-HT2Aand 5-HT1Breceptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience”
SEC MD&A · August 14, 2026
EB-003 has advanced into IND-enabling studies.
“Our EB-003 program has completed short-term dose-range finding toxicology studies and has advanced into IND-enabling, GLP compliant safety pharmacology, ADMET and longer-term toxicology studies.”
SEC MD&A · August 14, 2026
Enveric's Psybrary includes 20 patent families covering a million potential molecular structures.
“the Psybrary™, which currently includes 20 patent families with claims covering a million potential molecular structures”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Preclinical stage risk — EB-003 is in preclinical development; failure in IND-enabling studies or clinical trials could halt progress [sec_mda · as of 2026-08-14].
- Financial sustainability — Net loss of -$3.0M in Q2 2026 and no revenue; continued losses may require additional financing [sec].
- Regulatory uncertainty — No IND filed yet; FDA approval process is lengthy and uncertain [sec_mda · as of 2026-08-14].
- Competitive landscape — Other companies are developing non-hallucinogenic neuroplastogens, which could limit market opportunity [sec_mda · as of 2026-08-14].
What to watch
- IND filing for EB-003, expected next step per company disclosures [sec_mda · as of 2026-08-14].
- Progress of EVM401 Series pipeline expansion and any preclinical data [sec_mda · as of 2026-08-14].
- Financial updates, including cash runway and any new financing rounds [sec].
- Regulatory milestones, such as FDA feedback on IND-enabling studies [sec_mda · as of 2026-08-14].
Sources: SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run Enveric Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Enveric Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.11 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$107K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 32,149 | $62K |
| advisorshares investments llc | 16,974 | $33K |
| ubs group ag | 3,612 | $7K |
| tower research capital llc (trc) | 1,103 | $2K |
| jones financial companies lllp | 1,000 | $2K |
| sbi securities co., ltd. | 83 | $161 |
| blackrock, inc. | 51 | $99 |
| danske bank a/s | 1 | $2 |
| group one trading llc | 1 | $2 |
| national bank of canada /fi/ | 1 | $2 |
Showing top 10 of 11 institutional holders of Enveric Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 45.7%
- Days to cover
- 0.1
- Shares short
- 886,509
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Enveric Biosciences, Inc.?
Enveric Biosciences, Inc. is a biotechnology company developing novel neuroplastogenic small-molecule therapeutics for psychiatric disorders, with its lead candidate EB-003 in preclinical development.
What is Enveric Biosciences, Inc.'s lead drug candidate?
Enveric Biosciences, Inc.'s most advanced tracked candidate is eb-003 (Preclinical) for Mental health indication.
Who is the CEO of Enveric Biosciences, Inc.?
Dr. Joseph Edward Tucker Ph.D. is the chief executive officer of Enveric Biosciences, Inc. (ENVB).
Where is Enveric Biosciences, Inc. headquartered?
Enveric Biosciences, Inc. (ENVB) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Enveric Biosciences, Inc. focus on?
Enveric Biosciences, Inc. develops therapies across Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.